

Northeastern University & OMSiH Internal Meeting

Friday, April 17, 2015

Conference Call

|  |  |
| --- | --- |
| **One Million Solutions in Health** | **Northeastern University** |
| **Present:**  Dawn Van Dam  Brett Johnson  **Absent:**  Ashlee Woolfson | **Present:**  Ahmed Busnaina  Cihan Yilmaz  **Absent:**  Eric Howard |

Agenda:

1. Signature Square
2. Grant Update
3. Business Development: Biolome
4. Business Development: Nanorods
5. TEC Project Update

**I) Signature Square**

* OMSiH requires an abstract from Northeastern. It should be a general abstract, as if for a peer reviewed article. It should be worded such that people who are not subject matter experts can understand it enough to pass it on to the right people, but that the experts will recognize that it is new in the field. It should be 150 words in length.
  + Northeastern asked if they should include detection of bacteria and viruses in the abstract, or is it irrelevant for pharmaceutical companies? Brett answered that if the scope of the technology allows it there is no reason to leave it out.
  + Ahmed agreed to send the abstract this weekend.
* Ahmed will send OMSiH supplemental information as well
* The date of the event is May 28th
  + The actual presentation is 11am – 12pm but we blocked off the calendar from 10:30 – 12:30.
* There were two people NEU had mentioned to invite to be part of the presentation: Ahmed is looking at their availability
* Ahmed is also going to start thinking about people he wants to start inviting – even just company names that Brett can look in to.
  + We will create a google doc to drop names

**II) Grant Update**

* The grant has been submitted.
* Brett would like a copy of the text; Cihan will send it to him.
* OMSiH asked if Mimi sent a letter of support? Northeastern replied that they did not ask her; the letter should be coming from companies and as far as we know she is not part of a company right now.

**III) Business Development: Biolom**

* Dawn asked if Northeastern is still interested in commercializing Biolom.
* She explained that a meeting would need to be set up with everyone involved.
* Cihan will send an older version of the business plan to Brett, which still be valid, and copy Ahmed
* Brett would also like an update on the science and any data available.

**IV) Business Development: Nanorods**

* Past experience has shown that pharma is more likely to work with a company rather than a university
  + Ahmed can start talking to the university about an IP
  + Dawn proposed that HealthConnexions would become an investor in this new company, where each investor can negotiate their responsibilities (i.e. marketing, science etc.)
  + The sales will come, but the company needs to be set up.
* Ahmed wants a separate meeting in person to talk about this
* To start: Ahmed will create a one pager about milestones

**V) TEC Project Current Status**

* Cihan has presented all the results he has so far
* At the next project meeting we will need to start talking about the next phase: cell permeability studies
* To complete phase I we still need the last two compounds: Rifmaxin and cyclosporine
* Allergan will send cyclosporine; they need a one page from Brett first on the project (why we’re doing it and what we’ve done) in order for them to send the drug
  + They chose cyclosporine because there is a lot of legacy data
* The agreement with J&J is centered around the status of a non-disclosure agreement; it needed to be updated and as soon as that paperwork gets solved we can move forward. They have a very insoluble drug; we should get information on this drug soon; Brett has a call scheduled with Danny on Monday.
* What are the questions we should be looking at that are important to pharma? If Brett can send those questions to Cihan he can look into it.

**Action Items:**

1. **Ahmed** should send OMSiH an abstract for the Signature Square by Monday April 20th.
2. **Ahmed** will send OMSiH supplemental information for the Signature Square presentation
3. **Ahmed** will check the availability of the other people he wanted to present at the Signature Square webinar
4. **Ahmed** will begin to think of names/companies he wants present at the Signature Square webinar; **Ashlee** will create a google doc so that everyone has access to the names.
5. **Cihan** will send Brett a copy of the grant
6. **Cihan** will send Brett the business development plan for Biolom as well as any updated data
7. **Ahmed** will start to talk to the university about an IP
8. **Ahmed** will create a one-pager about goals for the nanorods business development
9. **Brett** will continue to work with pharma companies to get the rest of the drugs to Cihan so he can complete the phase I experiments.
10. **Brett** will send Cihan the questions that are important for pharma that he should be looking in to.